NCT07781709Not yet recruiting
Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-Substudy
Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-Penn Pilot Low Load Resistance Exercise Training Substudy
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
After completion of the Baseline study visit for the main study (MUSCLE UP-PH), participants at the University of Pennsylvania location will be invited to participate in an optional substudy. The substudy will implement a low-load resistance exercise training for the lower extremities, focusing primarily on the gastrocnemius muscles. The goal of this intervention is to understand how low-load resistance training will impact blood flow and oxygen tissue extraction on the lower legs.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 17 Aug 2026
- Start date
- 30 Sept 2026
- Primary completion date
- 1 Jul 2029
- Lead sponsor
- University of Pennsylvania
- NCT number
- NCT07781709
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 30 Sept 2026 to the primary completion date, 1 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior to enrollment, evidence of moderately severe obstructive ventilator defect with:
- Prior to enrollment, evidence of severe restrictive defect with
Other illness
- More than moderate aortic or mitral valve disease
Lab values
- LVEF \< 40% within 1 year of screening
Other
- FEV1/FVC ≤ 5th percentile; and
- FEV1 z-score \< -2.5
- TLC \< 5th percentile
- FEV1 z-score \< -4
- Pregnancy
Who the study is looking for
- Signed informed consent prior to initiation of any study mandated procedure.
- Male and female patient's ≥ 18 years of age.
- Diagnosis of PAH belonging to one of the following subgroups of Group 1 PH according to the updated clinical classification \[Humbert 2022\]
- Idiopathic (IPAH)
- Heritable (HPAH)
- Drugs or toxins induced
- Associated (APAH) with one of the following:
- Connective tissue disease;
- Human immunodeficiency virus (HIV) infection;
- Congenital heart disease; or
- Portopulmonary hypertension
- Diagnosis of PAH within 6 months of enrollment or diagnosis of PAH and on stable therapy for 3 months prior to enrollment
- Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC), prior to enrollment showing:
- mPAP \> 20 mmHg; and
- PAWP or LVEDP ≤ 15 mmHg
- PVR \> 2 Wood units
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Hospital Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.